Drug intelligence / Profile preview

NUC-404

Development stage: Preclinical
Lead developer: NuCana
Modality: Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules

Overview

NUC-404 is an anti-viral agent developed by Nucorion Pharmaceuticals for the treatment of hepatitis B. It utilizes Ligand Pharmaceuticals' Liver Targeting Prodrug (LTP) technology, which was licensed to Nucorion. The drug is part of an initial program focused on the China market.

Beyond the preview

Go deeper on NUC-404.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NUC-404.

Explore the full profile